We are seeing patients in-person and through Video Visits. Learn more about how we’re keeping you safe and please review our updated visitor policy. Please also consider supporting Weill Cornell Medicine’s efforts to support our front-line workers.
Impact of the FDA Approval of CTL019 in ALL
Wednesday, August 30, 2017
Gail J. Roboz, M.D., a professor of medicine and director of the Clinical and Translational Leukemia Program at Weill Cornell Medicine/NewYork-Presbyterian Hospital, spoke to OncLive about the impact of the FDA approval of tisagenlecleucel (CTL019; Kymriah) in select pediatric and young adult patients with a form of acute lymphoblastic leukemia (ALL).